Tao Sun
- Oncology top 5%
- HER2/EGFR in Cancer Research 29
- Cancer Treatment and Pharmacology 22
- Cancer-related Molecular Pathways 7
- Lung Cancer Research Studies 7
-
- Advanced Breast Cancer Therapies 31
- Cancer Research top 10%
- Breast Cancer Treatment Studies 8
- Genetics top 10%
-
- Monoclonal and Polyclonal Antibodies Research 10
-
- Gut microbiota and health 6
- Co-authors
- Junnan XuBruce NealNgozi EronduQiang LiDick de ZeeuwDavid R. MatthewsGreg FulcherWayne Shaw
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Tao Sun
81 papers receiving 1.4k citations
Hit Papers
Peers
Comparison fields: 5 of 100
- Oncology 672
- Endocrinology, Diabetes and Metabolism 335
- Pulmonary and Respiratory Medicine 451
- Cancer Research 185
- Genetics 84
Countries citing papers authored by Tao Sun
This map shows the geographic impact of Tao Sun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tao Sun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tao Sun more than expected).
Fields of papers citing papers by Tao Sun
This network shows the impact of papers produced by Tao Sun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tao Sun. The network helps show where Tao Sun may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Tao Sun, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trialbreakdown → | 2025 | 16 |
| 2 | 2025 | 0 | |
| 3 | 2025 | 5 | |
| 4 | 2024 | 35 | |
| 5 | 2024 | 10 | |
| 6 | 2024 | 7 | |
| 7 | 2024 | 1 | |
| 8 | 2024 | 0 | |
| 9 | 2023 | 4 | |
| 10 | 2023 | 39 | |
| 11 | 2023 | 11 | |
| 12 | 2023 | 27 | |
| 13 | 2022 | 2 | |
| 14 | 2021 | 7 | |
| 15 | 2020 | 17 | |
| 16 | 2020 | 7 | |
| 17 | 2020 | 29 | |
| 18 | 2020 | 7 | |
| 19 | 2019 | 17 | |
| 20 | Canagliflozin for Primary and Secondary Prevention of Cardiovascular Eventsbreakdown → | 2017 | 375 |
About Tao Sun
Tao Sun is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 92 papers that have together received 1.4k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (31 papers), HER2/EGFR in Cancer Research (29 papers), Cancer Treatment and Pharmacology (22 papers), Monoclonal and Polyclonal Antibodies Research (10 papers), Breast Cancer Treatment Studies (8 papers), Cancer-related Molecular Pathways (7 papers), Lung Cancer Research Studies (7 papers) and Gut microbiota and health (6 papers). The work is most often cited by research in Oncology (672 citations), Endocrinology, Diabetes and Metabolism (335 citations) and Pulmonary and Respiratory Medicine (451 citations). Tao Sun has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Junnan Xu, Bruce Neal, Ngozi Erondu, Qiang Li, Dick de Zeeuw, David R. Matthews, Greg Fulcher, Wayne Shaw, Vlado Perkovic and Kenneth W. Mahaffey. Their work appears in journals such as Circulation, Nature Medicine and Nature Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.